Catalyst Pharmaceuticals Q1 2023 Earnings Report

Catalyst Pharmaceuticals EPS Results

• Actual EPS: $0.26
• Consensus EPS: $0.30
• Beat/Miss: Missed by -$0.04
• One Year Ago EPS: N/A

Catalyst Pharmaceuticals Revenue Results

• Actual Revenue: $85.37 million
• Expected Revenue: $83.04 million
• Beat/Miss: Beat by +$2.33 million
• YoY Revenue Growth: N/A

Catalyst Pharmaceuticals Announcement Details

• Quarter: Q1 2023
• Date: 5/10/2023
• Time: N/A

Catalyst Pharmaceuticals (NASDAQ:CPRX), a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.